Sarepta Therapeutics
Stock Forecast, Prediction & Price Target
Sarepta Therapeutics Financial Estimates
Sarepta Therapeutics Revenue Estimates
Sarepta Therapeutics EBITDA Estimates
Sarepta Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $701.88M N/A | $933.01M 32.92% | $1.24B 33.26% | Avg: $3.27B Low: $3.27B High: $3.27B avg. 163.65% | Avg: $3.96B Low: $3.96B High: $3.96B avg. 20.93% | Avg: $4.31B Low: $4.31B High: $4.31B avg. 8.85% | Avg: $4.62B Low: $4.62B High: $4.62B avg. 7.10% |
Net Income
% change YoY
| $-418.78M N/A | $-703.48M -67.98% | $-535.97M 23.81% | Avg: $1.14B Low: $1.14B High: $1.14B avg. 314.08% | Avg: $1.70B Low: $1.70B High: $1.70B avg. 49.00% | Avg: $1.44B Low: $1.44B High: $1.44B avg. -15.29% | Avg: $1.62B Low: $1.62B High: $1.62B avg. 11.99% |
EBITDA
% change YoY
| $-412.11M N/A | $-473.53M -14.90% | $-439.19M 7.25% | Avg: $-2.15B Low: $-2.15B High: $-2.15B avg. -391.13% | Avg: $-2.60B Low: $-2.60B High: $-2.60B avg. -20.93% | Avg: $-2.83B Low: $-2.83B High: $-2.83B avg. -8.85% | Avg: $-3.04B Low: $-3.04B High: $-3.04B avg. -7.10% |
EPS
% change YoY
| -$5.15 N/A | -$8.03 -55.92% | -$5.8 27.77% | Avg: $12.42 Low: $12.42 High: $12.42 avg. 314.11% | Avg: $18.5 Low: $18.5 High: $18.5 avg. 49.00% | Avg: $15.68 Low: $15.68 High: $15.68 avg. -15.29% | Avg: $17.56 Low: $17.56 High: $17.56 avg. 11.99% |
Operating Expenses
% change YoY
| $1.05B N/A | $1.32B 26.04% | $1.36B 2.37% | Avg: $1.71B Low: $1.71B High: $1.71B avg. 25.77% | Avg: $2.06B Low: $2.06B High: $2.06B avg. 20.93% | Avg: $2.25B Low: $2.25B High: $2.25B avg. 8.85% | Avg: $2.41B Low: $2.41B High: $2.41B avg. 7.10% |
FAQ
What is Sarepta Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 89.94% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is 1.14B, average is 1.14B and high is 1.14B.
What is Sarepta Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 50.13% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $3.27B, average is $3.27B and high is $3.27B.
What is Sarepta Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 89.95% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is $12.42, average is $12.42 and high is $12.41.